| Drug Name | 
								Regadenoson | 
							
							
								| Drug ID | 
								BADD_D01921 | 
							
							
								| Description | 
								Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008. | 
							
							
								| Indications and Usage | 
								Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)  | 
							
							
								| Marketing Status | 
								approved; investigational | 
							
				
							
								| ATC Code | 
								C01EB21 | 
							
							
								| DrugBank ID | 
								
									DB06213
								 | 
							
							
								| KEGG ID | 
								
									D05711
								 | 
							
							
								| MeSH ID | 
								
								
									C430916
								 	
								
								 | 
							
							
								| PubChem ID | 
								
									219024
								 | 
							
							
								| TTD Drug ID | 
								
									D0XE1C
								 | 
							
							
								| NDC Product Code | 
								55150-443; 0409-1401; 76329-3321; 42973-229; 76055-0024; 60505-6116; 72611-874; 59285-029; 69766-103; 68083-175; 16729-477; 71288-201; 0641-6253; 65129-1331; 43598-616; 0469-6501; 62147-0220; 36000-364 | 
							
							
								| UNII | 
								
                                    2XLN4Y044H
                                 | 
							
							
								| Synonyms | 
								regadenoson | Lexiscan | CVT 3146 | CVT3146 | CVT-3146 |